Developments Progenics Pharma completes enrollment in Phase 3 prostate cancer detection trial Progenics Pharmaceuticals (NASDAQ:PGNX) completed enrollment for its Phase 3 study testing the diagnostic performance and clinical impact of 18F-DCFPyL (PyL) in men with recurrent prostate cancer. PyL, a small molecule... August 6, 2019